Aditxt, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.aditxt.com

Moat Score

Market Cap $592.21
PE -0
Debt $8.37M
Cash $328.60K
EV $8.04M
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$46.25M
EBIT	-$30.16M
ROE	-982%
ROA	-101%
Equity	$4.71M
Growth Stability	1
PE	-0
PB	0
P/S	0
Price/Cash	554.86
Debt/Equity	1.78
Net Margins	-27K%
Gross Margins	-297%
Op. Margins	-14K%
Sales Growth YoY	-94%
Sales Growth QoQ	-85%
Sales CAGR	-4%
Equity CAGR	-11%
Earnings Growth YoY	27%
Earnings Growth QoQ	66%

Sales CAGR 5Y	-8%
Equity CAGR 5Y	-13%
Earnings CAGR 3Y	-53%
Sales CAGR 3Y	-53%
Equity CAGR 3Y	16%
Market Cap	$592.21
Revenue	$212.11K
Assets	$29.84M
Total Debt	$8.37M
Cash	$328.60K
Shares Outstanding	1.68K
EV	8.04M
Moat Score	0%
Working Capital	-22.28M
Current Ratio	0.09
Gross Profit	-$630.23K
Shares Growth 3y	-0%
Equity Growth QoQ	-28%
Equity Growth YoY	-212%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Aditxt Inc is a life sciences company which focuses on prolong life and enhance life quality of transplanted patients. The firm develop products designed to induce tolerance to transplanted organs. The firm's immunosuppressive (anti-rejection) drugs has made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues.

SEC Filings

Direct access to Aditxt, Inc. (ADTX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Aditxt, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Aditxt, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Aditxt, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Aditxt, Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-44K%	-3K%	-5K%	-27K%
ROA	-	-68%	-252%	-237%	-58%	-101%
ROE	-	-85%	-455%	-531%	-204%	-982%

Bad Net Margins (-26.85K%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-0.01	-0.84	-
Debt over Equity	-0.05	-	-	0.03	0.97	1.78
Growth Stability	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Bad Debt/Equity ratio (1.78)

The company is overleveraged and has a bad balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	789%	-31%	-8%
Earnings YoY growth	-	60%	397%	-40%	18%	-
Equity YoY growth	-	-486%	-8%	-49%	208%	-13%
FCF YoY growth	-	-	215%	-2%	-18%	-